Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis

Documenti analoghi

• Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
  di: Taylor, P, et al.
  Pubblicazione: (2021)
• Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
  di: Weinblatt, M, et al.
  Pubblicazione: (2017)
• Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials
  di: Weinblatt, M, et al.
  Pubblicazione: (2018)
• Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
  di: Taylor, P, et al.
  Pubblicazione: (2019)
• Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
  di: Gerd Burmester, et al.
  Pubblicazione: (2020-02-01)